Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy

Zhang, Lilong; Chen, Chen; Chai, Dongqi; Li, Chunlei; Kuang, Tianrui; Liu, Li; Dong, Kai; Deng, Wenhong; Wang, Weixing

doi:10.3389/fphar.2022.1018411

Cited by 5 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A sensitivity analysis was performed by removing a single study. Publication bias was assessed using Begg’s and Egger’s tests ( 25 , 26 ).…”

Section: Methodsmentioning

confidence: 99%

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Qi,

Qiao,

Song

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe newly discovered pan-immune-inflammation value (PIV) has been illustrated to have good prognostic value for cancer patient prognosis. However, the prognostic usefulness of PIV in breast cancer patients is unknown. As a result, to aid the clinic in providing a distinctive and trustworthy biomarker to better assess breast cancer patient’s prognosis, we conducted this meta-analysis to investigate the relationship between PIV and the survival of breast cancer patients.MethodsWe conducted a systematic search of Pubmed, Embase, the Cochrane Library, and the CNKI databases to screen for eligible studies published up to April 2023. Outcomes included overall survival (OS), progression-free survival (PFS), and pathological complete response (pCR). The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the indicators. STATA 15.0 software was used to perform meta-analysis, sensitivity analysis, and publication bias analysis.ResultsA total of eight articles, involving 2953 patients, met the inclusion criteria and were included in this meta-analysis. The results showed that patients with higher PIV levels had a significantly shorter OS (HR: 2.045, 95% CI: 1.355-3.086, P = 0.001) and PFS (HR: 1.466, 95% CI: 1.163-1.848, P = 0.001). Besides, the PIV value was negatively correlated with the efficacy of neoadjuvant chemotherapy. Sensitivity analysis showed that the results of this study were reliable and stable.ConclusionsPIV has a good prognostic value in breast cancer patients and is expected to be a prognostic biomarker for breast cancer.

show abstract

“…A sensitivity analysis was performed by removing a single study. Publication bias was assessed using Begg’s and Egger’s tests ( 25 , 26 ).…”

Section: Methodsmentioning

confidence: 99%

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Qi,

Qiao,

Song

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Immune checkpoints, proteins expressed by T cells, regulate T cell function and act as gatekeepers of the immune response to prevent autoimmunity. Immune checkpoint inhibitors are designed to release damaged T cells and thus induce an anti-tumor response [ 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma

Li,

Tianrui,

Chunlei

et al. 2023

Aging

View full text Add to dashboard Cite

Background: The advent of immune checkpoint inhibitors (ICIs) has altered the outlook for cancer treatment. The estimation of predictive biomarkers could contribute to maximizing the benefits from ICIs treatment. Here, we explored the association between HYDIN mutations (HYDIN-MUT) in melanoma and ICIs efficacy. Methods: Clinical data and sequencing data from published studies were utilized to assess the association between HYDIN-MUT and the efficacy of ICIs treatment in melanoma patients. Results: Compared to other tumor types, HYDIN (36.14%) has the highest mutation rate in melanoma patients. In the anti-PD-1 treated cohort (n = 254), the HYDIN-MUT patients had a longer OS after ICIs treatment than the HYDIN wild-type (HYDIN-WT) patients (HR = 0.590 [95% CI, 0.410-0.847], P = 0.004); the objective response rate (ORR) and durable clinical benefit (DCB) were increased in patients with HYDIN-MUT (ORR = 46.25, DCB = 56.00%) compared to patients with HYDIN-WT (ORR = 30.99%, DCB = 42.76%) (ORR: P = 0.019; DCB: P = 0.060). In the anti-CTLA4 treated cohort (n = 174), HYDIN-MUT patients achieved significantly longer OS than HYDIN-WT patients (HR = 0.549 [95% CI, 0.366-0.823], P = 0.003); the proportion of ORR and DCB in HYDIN-MUT patients was significantly higher than that in HYDIN-WT patients (ORR 40.54% vs. 14.42%, P = 0.031; DCB 45.76% vs. 22.22%, P = 0.002). Further gene set enrichment analysis demonstrated that DNA repair and anti-tumor immunity were significantly enhanced in HYDIN-MUT patients. Conclusions: HYDIN mutations are a potential predictive biomarker of ICIs efficacy in melanoma patients.

show abstract

“…Table 1 summarizes the basic characteristics of the 23 included publications (10)(11)(12)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44). These publications were from China (n=19), the United States of America (n=2), Australia (n=1), and France (n=1).…”

Section: Basic Characteristicsmentioning

confidence: 99%

Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review

Li,

Zhang,

Yang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionCancer is a major global health concern, and immune checkpoint inhibitors (ICIs) offer a promising treatment option for cancer patients. However, the efficacy of ICIs can be influenced by various factors, including the use of concomitant medications.MethodsWe searched databases (PubMed, Embase, Cochrane Library, Web of Science) for systematic reviews and meta-analyses for systematic reviews and meta-analyses on the impact of concomitant medications on ICIs efficacy, published from inception to January 1, 2023. We evaluated the methodological quality of the included meta-analyses, and re-synthesized data using a random-effects model and evidence stratification.ResultsWe included 23 publications, comprising 11 concomitant medications and 112 associations. Class II-IV evidence suggested that antibiotics have a negative impact on ICIs efficacy. However, ICIs efficacy against melanoma, hepatocellular carcinoma, and esophageal squamous cell carcinoma was not affected, this effect was related to the exposure window (class IV). Class III evidence suggested that proton pump inhibitors have a negative impact on ICIs efficacy; nevertheless, the efficacy against melanoma and renal cell carcinoma was not affected, and the effect was related to exposure before the initiation of ICIs therapy (class II). Although class II/III evidence suggested that steroids have a negative impact, this effect was not observed when used for non-cancer indications and immune-related adverse events (class IV). Class IV evidence suggested that opioids reduce ICIs efficacy, whereas statins and probiotics may improve ICIs efficacy. ICIs efficacy was not affected by histamine 2 receptor antagonists, aspirin, metformin, β-blockers, and nonsteroidal anti-inflammatory agents.ConclusionCurrent evidence suggests that the use of antibiotics, PPIs, steroids, and opioids has a negative impact on the efficacy of ICIs. However, this effect may vary depending on the type of tumor, the timing of exposure, and the intended application. Weak evidence suggests that statins and probiotics may enhance the efficacy of ICIs. Aspirin, metformin, β-blockers, and NSAIDs do not appear to affect the efficacy of ICIs. However, caution is advised in interpreting these results due to methodological limitations.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO,identifier, CRD42022328681.

show abstract

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy

Cited by 5 publications

References 39 publications

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Clinical utility of the pan-immune-inflammation value in breast cancer patients

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma

Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review

Contact Info

Product

Resources

About